National centre for LAM

For guidance on shielding from COVID-19 please download the below document

For guidance on Coronavirus Vaccines and the National Centre for LAM please download the below document

Lymphangioleiomyomatosis (LAM) is a rare multi-system disease, which almost exclusively affects women. LAM can cause progressive loss of lung function, leading to breathlessness, lung collapse and lymphatic problems in the chest and abdomen.

The National Centre for Lymphangioleiomyomatosis (LAM) is a comprehensive clinical service for patients with LAM. It provides clinical care:

  • diagnostic workup of patients with suspected LAM
  • ongoing respiratory care either exclusively at the centre or in partnership with local providers
  • clinical and genetic evaluation of Tuberous Sclerosis Complex (TSC) in patients with LAM and evaluation of LAM in patients with TSC
  • evaluation and monitoring of renal angiomyolipoma
  • surgical assessment and treatment of complications
  • pre lung transplant evaluation and referral

In conjunction with the University of Nottingham, the LAM centre is also a hub for clinical trials of new therapies for LAM, evaluation of biomarkers, outcome and laboratory research into the molecular basis of the disease.